IGF2BP3 and hepatocellular carcinoma: The dysregulated expression of IGF2BP3 was further validated in the independent dataset GSE14520 (Fig. 2E,F). Patients with HCC with cirrhosis, high AFP levels, and advanced CLIP stages had higher IGF2BP3 expression (Fig. 2G).